Kazuhiko Koike

Publications (13)27.33 Total impact

• Article: Response.

  Hiroshi Kawakami, Hiroyuki Isayama, Hiroyuki Maguchi, Masaki Kuwatani, Yousuke Nakai, Kazumichi Kawakubo, Shin Haba, Taiki Kudo, Yoko Abe, Kazuhiko Koike, Naoya Sakamoto
  Gastrointestinal endoscopy 10/2012; 76(4):920-1. · 6.71 Impact Factor
• Article: Long-Term Survival and Late-Onset Complications of Cancer Patients Treated With High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation

  Kyuhei Kohda, Sumio Sakamaki, Takuya Matsunaga, Takashi Kuga, Akihito Fujimi, Yuichi Konuma, Toshiro Kusakabe, Katsuhisa Kogawa, Takehide Akiyama, Kazuhiko Koike, Yasuo Hirayama, Yutaka Sasagawa, Syuichi Nojiri, Yasuji Hirata, Takuji Nishisato, Yoshiro Niitsu, Hokkaido Society of Peripheral Blood Stem Cell Transplantation
  [show abstract] [hide abstract]
  ABSTRACT: The antitumor effect of high-dose chemotherapy (HDC) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) is considered superior to that of conventional chemotherapy. However, the long-term benefits of this strategy in Japan remain unclear.Therefore, in this study, 109 cancer patients enrolled between 1989 and 1999 were treated with HDC and auto-PBSCT. Patients were evaluated for long-term survival and late-onset complications, including secondary malignancy. The mean number of CD34+ cells harvested per apheresis was larger in the group receiving high-dose cytosine arabinoside or high-dose etoposide plus granulocyte colony-stimulating factor (G-CSF) than in the group receiving conventional chemotherapy plus G-CSF. The 5-year overall survival rates for non-Hodgkin’s lymphoma patients in first complete remission (CR) (83.2%), second or subsequent CR (74.1%), or first partial remission (PR) (66.7%) at the time of transplantation were significantly higher than those with no remission (35.7%) at the time of transplantation (first CR,P < .05; second or subsequent CR,P < .05; first PR,P < .05). The 5-year overall survival (OS) rates for breast cancer was 40.8%, and the disease-free survival rate was extremely low (8.8%). The 5-year OS rates for chemotherapy-sensitive and chemotherapy-resistant diseases at the time of transplantation were 32.7% and 35.7%, respectively, a difference that was not considered significant. The 5-year OS for germ cell tumor was 80.0%, and the disease-free survival rate was 77.9%. The rate of therapy-related death was 8.2%. The occurrence rate of secondary malignancy was 0.9%. Late-onset complications were observed in 4 cases (glomerulonephritis, interstitial pneumonitis, ulcerative colitis, and acute myelogenous leukemia). At 3.7%, the occurrence rate was not very high, but most complications of auto-PBSCT were life threatening and interfered with patients’ quality of life. A careful follow-up is required for at least 2 years after transplantation, because the mean occurrence time of late-onset complications is 16.7 months posttransplantation.
  International Journal of Hematology 04/2012; 73(2):251-257. · 1.27 Impact Factor
• Article: [Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].

  Yasuo Hirayama, Takeshi Terui, Kazuhiko Koike, Hiroshi Neda, Kunihiko Ishitani, Kyuhei Kohda, Hiroyuki Kuroda, Satoshi Iyama, Tsutomu Sato, Masayoshi Kobune, Rishu Takimoto, Junji Kato
  [show abstract] [hide abstract]
  ABSTRACT: The institutional review board of our hospital approved FLAG-MG therapy (G-CSF 300 microg day 1-6, fludarabin 30 mg/m(2) day 2-6, Ara-C 1 g/m(2) day 2-6, mitoxantrone 5 mg/m(2) day 2-4, gemtuzumab ozogamicin 3 mg/m(2) day 9) for relapsed or refractory elderly acute myeloid leukemia patients. We conducted this therapy for two refractory patients aged 56 and 63 and one relapsed 58-year-old patient. All three patients were induced complete remission after FLAG-MG therapy without serious complications.
  [Rinshō ketsueki] The Japanese journal of clinical hematology 08/2009; 50(8):663-5.
• Article: [Acute myelogenous leukemia with multilineage myelodysplasia, positive direct Coombs test, and elevated levels of platelet-associated IgG].

  Hiroyuki Kuroda, Takuya Matsunaga, Sumio Sakamaki, Kazuhiko Koike, Takeshi Terui, Hiroshi Neda, Kunihiko Ishitani, Atsushi Nobuoka, Masaya Kida, Hideki Watanabe, Yoshiro Niitsu
  [show abstract] [hide abstract]
  ABSTRACT: A 75-year-old man was admitted to our hospital in October, 2005 for examination of pre-diagnosed pancytopenia. His bone marrow showed myeloid dysplasia, and 30.4% of the nucleated cells were blasts. Our diagnosis was acute myelogenous leukemia with multilineage myelodysplasia (AML with MLD; WHO classification). A direct Coombs test proved positive, and the platelet-associated IgG (PA-IgG) level was elevated. After treatment with CAG (Ara-C + ACR + G-CSF), complete remission was obtained, showing negative on the direct Coombs test with PA-IgG levels returned to normal. The patient subsequently relapsed, testing positive on the direct Coombs test and experiencing a re-elevation of PA-IgG levels. We report here a first case of AML with MLD, direct Coombs test and PA-IgG assay.
  [Rinshō ketsueki] The Japanese journal of clinical hematology 06/2007; 48(5):407-11.
• Article: [T-cell rich B-cell lymphoma associated with neutrophilia and thrombocytosis].

  Hiroyuki Kuroda, Takuya Matsunaga, Sumio Sakamaki, Kazuhiko Koike, Takeshi Terui, Hiroshi Neda, Kunihiko Ishitani, Atsushi Nobuoka, Mutsumi Sato, Masaya Kida, Hideki Watanabe, Jun Yamaguchi, Yoshiro Niitsu
  [show abstract] [hide abstract]
  ABSTRACT: A 49-year-old man was admitted with high-grade fever, night sweating and cervical lymphadenopathy in September 2005. On examination, both neutrophilia and thrombocytosis were noted in the peripheral blood, a bone marrow examination revealed marked both myeloid and megakaryocytic hyperplasia. The sera obtained at initial presentation showed an elevated levels of granulocyte-colony stimulating factor (G-CSF) and interleukin-6 (IL-6). A pathologic diagnosis of T-cell rich B-cell lymphoma was made based on an inguinal lymph node biopsy. Following treatment with CHOP accompanied by rituximab (R-CHOP), both the neutrophilia and thrombocytosis subsided after 3 courses of R-CHOP, resulting in a complete remission after 4 courses of chemotherapy. Neutrophilia, thrombocytosis and T-cell rich B-cell lymphoma in this patient were considerably ameliorated with chemotherapy. We report here a patient with T-cell rich B-cell lymphoma associated with both neutrophilia and thrombocytosis, suggesting that the lymphoma triggered both myeloid and megakaryocytic hyperplasia.
  [Rinshō ketsueki] The Japanese journal of clinical hematology 04/2007; 48(3):217-22.
• Article: [A case of primary carcinoma of the cystic duct with limy bile].

  Sho Takahashi, Hisato Homma, Takehide Akiyama, Shinichi Mesawa, Kazuhiko Koike, Kenichiro Hirata, Katsuhisa Kogawa, Yutaka Kawano, Kohichi Takada, Tsutomu Sato, Yoshiro Niitsu
  [show abstract] [hide abstract]
  ABSTRACT: A 78-year-old man had been admitted to a previous hospital because of epigastralgia and a diagnosis of cholecystolithiasis had been made. He had been transferred to our institution for further examination. CT scan and US revealed chronic cholecystitis and gallstone, however, ERC revealed severe obstruction of the cystic duct and EUS revealed dilation of that duct and a solitary mass there. Carcinoma of the cystic duct was diagnosed, and we performed cholecystectomy and resection of the extrahepatic duct with two-field lymphadenectomy. The pathological specimen showed a round flat elevated mass localized in the cystic duct. Histopathologically, the diagnosis was well differentiated tubular adenocarcinoma of the cystic duct with limy bile and tiny gallstone.
  Nippon Shokakibyo Gakkai zasshi The Japanese journal of gastro-enterology 04/2007; 104(3):394-400.
• Article: [Intraperitoneal and intrapleural gemcitabine in patients with advanced pancreatic cancer].

  Takehide Akiyama, Hisato Homma, Shinichi Mezawa, Sho Takahashi, Kazuhiko Koike, Katsuhisa Kogawa, Kenichiro Hirata
  [show abstract] [hide abstract]
  ABSTRACT: We performed intraperitoneal and intrapleural dosing gemcitabine (GEM) to eight patients with advanced pancreatic cancer having peritoneal or pleural carcinomatosis and evaluated its actions and safety. GEM (500 mg/m2) was infused into the abdominal cavity or thoracic cavity after drainage of peritoneal or pleural effusion. We checked the change of serum GEM concentration and the side effects after the GEM administration. Then, we repeated the GEM administration observing their systematic symptoms and evaluated the alteration of peritoneal or pleural effusion and cytology. Plasma concentration of GEM by infusing into the abdominal cavity or thoracic cavity was lower than by intravenous injection. In three of the five cases of peritoneal carcinomatosis, intraperitoneal administration revealed a decrease of peritoneal effusion. In two of the three cases of pleural carcinomatosis, intrapleural administration revealed a decrease of pleural effusion. Four cases had leukocytopenia of grade 1/2, three cases had thrombocytopenia, and two cases had alopecia as side effects, although all of them were minor side effects. Intraperitoneal and intrapleural dosing GEM had minor side effects and could improve QOL for the patients with advanced pancreatic cancer associated with peritoneal or pleural carcinomatosis.
  Gan to kagaku ryoho. Cancer & chemotherapy 11/2005; 32(11):1712-4.
• Article: [Evaluation of the endoprosthesis by metallic stent and tube stent for malignant biliary stenosis].

  Sho Takahashi, Hisato Homma, Takehide Akiyama, Shinichi Mesawa, Kazuhiko Koike, Katsuhisa Kogawa, Kenichiro Hirata, Yoshiro Niitsus
  [show abstract] [hide abstract]
  ABSTRACT: We evaluated the effect of biliary endoprotheses for 20 malignant stenosis patients by an expandable metallic stent and hydrophilic heparinized tube (H-PSD) connected to an implantable port (IP), which reduces bacterial adherence. Group A consisted of 6 patients of cholangiocarcinoma who underwent hepatic arterial infusion chemotherapy associated with radiotherapy. Groups B and C consisted of 8 and 6 patients of stage IVa and IVb pancreatic carcinoma, respectively, who underwent hepatic and splenic arterial infusion chemotherapy following transcatheter peripancreatic arterial embolization. The 50% patent time was 12 months, 6 months and 7 months in groups A, B and C and the 50% overall survival time was 16 months, 23 months and 13 months, respectively. There were two complications, 1 case of infection around the IP in which the IP was withdrawn, and 3 cases of cholangitis in which we had easy access to the bile duct via IP. This technique appears to offer significant benefit in selecting patients with this type of biliary obstruction.
  Gan to kagaku ryoho. Cancer & chemotherapy 11/2005; 32(11):1630-2.
• Article: Enhanced expression of type IV collagen-binding protein (p29) in Fyn-transfected murine fibrosarcoma cells.

  Kazuhiko Koike, Katsuhisa Kogawa, Tetsuji Takayama, Naohito Yoshizaki, Hirohito Muramatsu, Kiminori Nakamura, Sumio Sakamaki, Yoshiro Niitsu
  [show abstract] [hide abstract]
  ABSTRACT: We investigated the mechanism of the enhancement of metastatic potential induced by transfection of the fyn gene, a member of the src family. We employed two murine fyn cDNA-transfected clones, ML-SN1 and ML-SN2, which were previously established from an ML-01 low-metastatic clone of Meth A sarcoma of BALB / c mice and were proven to have higher metastatic ability than ML-01 and the mock-transfected clone ML-MT-neo (Takayama et al., 1993). Our present investigation revealed that the two transfectants showed higher metastatic ability and higher rates of adherence to type IV collagen than ML-MT-neo. However, no difference was found in in vitro or in vivo growth rates, attachment to laminin or endothelial cells or cell motility through a reconstituted basement membrane. Analysis of surface membrane proteins labeled with (125)I on SDS-PAGE showed that a 29 kD band specifically bound to type IV collagen-coupled beads was more intense in ML-SN2 than in ML-MT-neo. Genistein, a protein tyrosine kinase inhibitor, dramatically reduced protein tyrosine kinase (PTK) activity of ML-SN2 in a dose-dependent fashion, corresponding to the reduction of adhesiveness to type IV collagen. The expression of the type IV collagen-binding protein (p29) of ML-SN2 was also reduced significantly by genistein treatment. These results suggested that the fyn product in Meth A cells augments the expression of a type IV collagen-binding protein through elevation of the PTK activity of the membrane fraction and thus facilitates the metastasis of Meth A.
  Japanese journal of cancer research: Gann 11/2002; 93(10):1090-9.
• Article: Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura.

  Kyuhei Kohda, Takashi Kuga, Katsuhisa Kogawa, Yuuji Kanisawa, Kazuhiko Koike, Ganji Kuroiwa, Yasuo Hirayama, Yasushi Sato, Yoshiro Niitsu
  [show abstract] [hide abstract]
  ABSTRACT: The prevalence of Helicobacter pylori infection and the effect of its eradication on platelet count in 48 Japanese patients with autoimmune thrombocytopenic purpura (AITP), including 40 chronic idiopathic thrombocytopenic purpura (ITP) and eight secondary AITP, were investigated. H. pylori infection was found in 25 ITP patients (62.5%) and in two secondary AITP (25%). H.pylori eradication was obtained in 19 of 19 infected ITP patients (100%), who were not in remission (platelets < 100 x 109/l) at the time of infection assessment. During follow-up (median 14.8 months), 12 of 19 H. pylori-eradicated patients (63.2%) showed a significant increase in platelet count accompanied by a significant decrease of platelet-associated immunoglobulin G (IgG). This response was maintained in all responding patients throughout the follow-up period. However, two infected patients with secondary AITP did not show platelet increase after eradication. The assessment of H. pylori infection and its eradication should be attempted in ITP as this approach could be an effective strategy, at least for some of these patients.
  British Journal of Haematology 08/2002; 118(2):584-8. · 4.94 Impact Factor
• Article: Enhanced inhibition of experimental metastasis by the combination chemotherapy of Cu-Zn SOD and adriamycin

  Katsuhisa Kogawa, Hirohito Muramatsu, Maki Tanaka, Yoshiki Nishihori, Seiya Hagiwara, Kageaki Kuribayashi, Kiminori Nakamura, Kazuhiko Koike, Sumio Sakamaki, Yoshiro Niitsu
  [show abstract] [hide abstract]
  ABSTRACT: We previously reported that reactive oxygen species (ROS) enhance tumor cell metastasis, and by administration of recombinant human superoxide dismutase (rhSOD), an enzyme which scavenges \textO\text2- {\text{O}}_{\text{2}}^ - successfully reduced lung metastasis of mouse MethA sarcoma and Lewis lung carcinoma. These observations suggested that rhSOD suppressed tumor cell invasion by eliminating \textO\text2- {\text{O}}_{\text{2}}^ - , the primary source of ROS. However, for the clinical application of the drug as an anti metastatic agent, rhSOD needs to be administered in combination with other cytotoxic agents, since SOD by itself has no cytotoxic activity. In this paper, we investigated the effectiveness of the combination chemotherapy of rhSOD and adriamycin (ADR), an anti-cancer agent against the experimental metastasis of highly metastatic clone, MH-02, which was derived from murine MethA sarcoma. The present metastasis experiment clearly indicates that the administration of rhSOD enhances the anti-metastatic effect of ADR. On the other hand, we found that the inhibition rate of metastasis exhibited by the combination chemotherapy of rhSOD and a certain dose (5mg/ml) of ADR was inferior to that of rhSOD. This apparent paradoxical phenomenon was presumably explained by our finding that tumor cells themselves augment their invasive capacity and platelet aggregation, both of which are causative factors for metastasis formation, by generation of \textO\text2- {\text{O}}_{\text{2}}^ - when they were treated with ADR. Nevertheless, the combination chemotherapy of SOD with anticancer drugs such as ADR can be a practical anti-metastasis strategy.
  Clinical and Experimental Metastasis 04/1999; 17(3):239-244. · 3.52 Impact Factor
• Article: Suppression of intracellular Cu‐Zn SOD results in enhanced motility and metastasis of Meth A sarcoma cells

  Maki Tanaka, Katsuhisa Kogawa, Yoshiki Nishihori, Kageaki Kuribayashi, Kiminori Nakamura, Hirohito Muramatsu, Kazuhiko Koike, Sumio Sakamaki, Yoshiro Niitsu
  [show abstract] [hide abstract]
  ABSTRACT: We have previously described an inverse relationship between Cu-Zn superoxide dismutase (SOD) activity and invasiveness of a clone of human tongue cancer cells. In these cells, suppression of Cu-Zn SOD activity by transfection with anti-sense cDNA enhanced motility in vitro. The present studies were undertaken to determine whether the inverse relationship between intracellular Cu-Zn SOD activity and motility is a general property of other tumor cells and whether this enzyme indeed defines in vivo metastatic potential. Murine Meth A sarcoma-derived ML-01 cells, which have low metastatic activity, were transfected with anti-sense Cu-Zn SOD cDNA. Two clones with very different SOD activities—ML-AS2, with the most suppressed, and ML-AS5, with the least suppressed activity—were analyzed for their motility and metastatic capability. Compared to the mock-transfectant ML-neo, the metastatic potential and motility of the ML-AS2 and ML-AS5 were increased 4.5- and 2.1-fold, respectively. Superoxide treatment enhanced the motility of the AS clones but not that of the ML-neo cells. Our results clearly show that there is an inverse relationship between the intracellular level of Cu-Zn SOD, cell motility and in vivo metastatic potential. Int. J. Cancer 73:187–192, 1997. © 1997 Wiley-Liss, Inc.
  International Journal of Cancer 12/1998; 73(2):187 - 192. · 5.44 Impact Factor
• Article: Suppressive effect of recombinant human Cu, Zn‐superoxide dismutase on lung metastasis of murtne tumor cells

  Naohito Yoshizaki, Yoshihiro Mogi, Hirohito Muramatsu, Kazuhiko Koike, Katsuhisa Kogawa, Yoshiro Niitsu
  [show abstract] [hide abstract]
  ABSTRACT: The inhibitory effect of recombinant human Cu++Zn++superoxide dismutase (rhSOD) on metastasis of tumor cells in the mouse was investigated. In an experimental pulmonary metastasis model employing Moth A cells as inoculum, significant inhibition of metastasis was obtained by intravenous pre- and post-administration of rhSOD. An inhibitory effect of rhSOD was also observed in a spontaneous pulmonary metastasis model with ILL cells as the inoculum. rhSOD was not observed to have any significant effects on the platelet-aggregating activity of tumor cells, the adhesiveness of tumor cells to vascular components (endothelial cells, laminin and type-IV collagen), or the growth of tumor cells either in vitro or in vivo. However, rhSOD suppressed invasion of Meth A and 3LL cells into Matrigel (an artificially reconstituted basement membrane of collagen, laminin and heparan sulfate) in the presence of hypoxanthine and xanthine oxidase, in vitro producers of superoxide. Thus, the present study shows that rhSOD is able to inhibit both experimental and spontaneous pulmonary metastasis, possibly through the suppression of tumor cell invasion into the extracellular matrix. © 1994 Wiley-Liss, Inc.
  International Journal of Cancer 04/1994; 57(2):287 - 292. · 5.44 Impact Factor